Navigation Links
Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes

BALTIMORE, Oct. 20 /PRNewswire/ -- Celsis International is pleased to announce that the United States Patent and Trademark Office today issued U.S. Patent No. 7,604,929 to Celsis In Vitro Technologies (Celsis IVT). This patent generally covers processes by which the company creates its unique LiverPool(TM) products for drug discovery research. The pooling process combines primary cells from multiple donors to create large lots with targeted activity levels. The resulting LiverPool product is flexible, customizable and repeatable, enabling scientists to run multiple studies on various compounds or NCEs anywhere in the world, and at any time, which speeds up decision making and reduces the time and cost of drug research.

"Our LiverPool product is a great example of Celsis IVT's pioneering work in developing ADME-Tox products that meet the research needs of our customers, while helping to take costs out of the drug discovery process," said Judy Madden, vice president of strategic development for Celsis. "We're proud that the US Patent Office has recognized our continued innovation and awarded us this patent."

Celsis IVT has been producing LiverPool products for more than five years and they have been incorporated into the standard research protocols of major pharmaceutical companies around the world. Research conducted with LiverPool has documented its efficacy as a research tool in numerous ADME-Tox assays, including metabolic stability and clearance studies. Scientific posters and LiverPool product information are available online at

About Celsis IVT

Celsis IVT is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development. Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization. Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research. Celsis IVT's patented LiverPool products, cryo-plateable hepatocytes (the world's largest inventory) and other ADMET research tools are available worldwide. Visit for more information.

About Celsis International

Chicago-based Celsis International is a leading global provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers. Celsis' extensive client base includes leading pharmaceutical and consumer products companies, including all 25 of the top 25 pharmaceutical companies worldwide. Visit

SOURCE Celsis International

SOURCE Celsis International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Chicago-Based Celsis International Goes Private
2. Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes
3. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
4. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
5. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
6. Celsis Receives Frost & Sullivan 2008 Best Practices Award
7. Peripheral Artery Disease (PAD) Patent Granted to Dimera
8. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
9. Delcath Systems Granted Third Orphan Drug Designation
10. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
11. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
Post Your Comments:
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):